GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.
Quick Facts
What This Study Found
GLP-1 RAs increase gallstone and gallbladder inflammation risk through suppression of cholecystokinin, altered bile acid composition, and rapid weight loss-related cholesterol supersaturation.
Key Numbers
Mechanisms: CCK suppression, bile acid alterations, weight loss-related cholesterol supersaturation; risk increases with dose and duration.
How They Did This
Narrative review of molecular mechanisms and clinical evidence for GLP-1 RA-associated biliary disease.
Why This Research Matters
Gallbladder problems are one of the most clinically significant side effects of GLP-1 drugs. Understanding the mechanisms could help prevent them.
What This Study Doesn't Tell Us
Narrative format. Absolute risk increase is modest. Difficult to separate drug effect from rapid weight loss effect. Prevention strategies not well established.
Trust & Context
- Original Title:
- GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.
- Published In:
- Therapeutic advances in endocrinology and metabolism, 16, 20420188251406456 (2025)
- Authors:
- Ramírez-Mejía, Mariana M, Ponciano-Rodriguez, Guadalupe, Eslam, Mohammed, Méndez-Sánchez, Nahum
- Database ID:
- RPEP-13193
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13193APA
Ramírez-Mejía, Mariana M; Ponciano-Rodriguez, Guadalupe; Eslam, Mohammed; Méndez-Sánchez, Nahum. (2025). GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.. Therapeutic advances in endocrinology and metabolism, 16, 20420188251406456. https://doi.org/10.1177/20420188251406456
MLA
Ramírez-Mejía, Mariana M, et al. "GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.." Therapeutic advances in endocrinology and metabolism, 2025. https://doi.org/10.1177/20420188251406456
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists and gallbladder disease risk: insigh..." RPEP-13193. Retrieved from https://rethinkpeptides.com/research/ramirez-mejia-2025-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.